A Phase 1, Open-label, Three-period, Fixed-sequence Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects

Trial Profile

A Phase 1, Open-label, Three-period, Fixed-sequence Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2012

At a glance

  • Drugs Apremilast; Rifampicin; Rifampicin
  • Indications Ankylosing spondylitis; Clostridium infections; Crohn's disease; Irritable bowel syndrome; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Traveller's diarrhoea
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 16 Oct 2012 Actual initiation date changed from Mar 2012 to Apr 2012 as reported by ClinicalTrials.gov.
    • 01 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top